Hyperprogressive disease with anti-PD-1 and anti-PD-L1

A new study by Stéphane Champiat (Gustave Roussy, Villejuif, France) and colleagues found that hyperprogressive disease was associated with older age (≥65 years) and worse overall survival in patients who had been treated with anti-PD-1/PD-L1 monoclonal antibodies.